KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication.

BACKGROUND AND OBJECTIVES Mutations of KIT receptor tyrosine kinase are involved in the constitutive activation and development of human hematologic malignancies. Gain-of-function mutations in the second intracellular kinase domain (TK2) and in the juxtamembrane domain are described in patients with core binding factor acute myeloid leukemia (CBFL) and are associated with leukocytosis. We evaluated the incidence of KIT mutation in 52 adult patients with de novo CBFL and in 49 FLT3/ITD-negative childhood patients with de novo acute myeloid leukemia (AML), excluding cases of acute promyelocytic leukemia. DESIGN AND METHODS In order to analyze the role of KIT in CBFL we examined the KIT mutations in 52 adult CBFL, including 15 previously reported patients, and in 49 non-APL childhood AML patients using sensitive detection methods. We correlated our findings with the presence of trisomy 4 and investigated the relationship of the extra chromosome 4 with KIT mutations. RESULTS Several kinds of gain-of-function KIT mutations were found in 24 of the 52 (46.1%) adult CBFL cases and 6 of the 49 (12.2%) non-APL childhood AML patients. KIT mutations were detected in 4 of the 8 adult patients and one childhood AML case bearing trisomy of chromosome 4 as either the sole cytogenetic aberration or a karyotypic aberration additional to t(8;21). In three of the trisomy 4 cases we demonstrated that trisomy 4 leads to duplication of the KIT mutated allele. INTERPRETATION AND CONCLUSIONS These results underline that the KIT gene is activated in AML characterized by distinct cytogenetic and molecular genetic patterns and represents the most frequently mutated target in adult CBFL.

[1]  I. Weissman,et al.  AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Downing,et al.  Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. , 2002, Cancer cell.

[3]  J. Reilly Class III receptor tyrosine kinases: role in leukaemogenesis , 2002, British journal of haematology.

[4]  J. Downing The core-binding factor leukemias: lessons learned from murine models. , 2003, Current opinion in genetics & development.

[5]  M. Valsecchi,et al.  FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia , 2003, British journal of haematology.

[6]  L. Larizza,et al.  Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia. , 2002, The hematology journal : the official journal of the European Haematology Association.

[7]  L. Castilla,et al.  Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11. , 2002, Blood.

[8]  R. Cairoli,et al.  C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index , 2003, Leukemia.

[9]  P. Peterlongo,et al.  C-kit mutations in core binding factor leukemias. , 2000, Blood.

[10]  J. Downing,et al.  Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience , 2002, Leukemia.

[11]  F. v.,et al.  Reply to SE Langabeer et al , 2003, Leukemia.

[12]  M. Fukayama,et al.  C‐kit Gene Abnormalities in Gastrointestinal Stromal Tumors (Tumors of Interstitial Cells of Cajal) , 1999, Japanese journal of cancer research : Gann.

[13]  L. Ashman,et al.  Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. , 2002, Molecular cancer therapeutics.

[14]  R. Cairoli,et al.  Trisomy 4 leading to duplication of a mutated KIT allele in acute myeloid leukemia with mast cell involvement. , 2000, Cancer genetics and cytogenetics.

[15]  J. Reilly,et al.  Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias , 2003, British journal of haematology.

[16]  C. Mecucci,et al.  Genetic profile of acute myeloid leukemia. , 2002, Reviews in clinical and experimental hematology.

[17]  T. Kyo,et al.  Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML , 2003, Leukemia.

[18]  D. Gilliland,et al.  Core-binding factors in haematopoiesis and leukaemia , 2002, Nature Reviews Cancer.

[19]  M. Caligiuri,et al.  Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Langabeer,et al.  AML with t(8;21) and trisomy 4: possible involvement of c-kit? , 2003, Leukemia.

[21]  T. Naoe,et al.  Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia , 1997, Leukemia.

[22]  J. Reilly,et al.  c‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia , 1999, British journal of haematology.

[23]  R. Arceci,et al.  Activating Mutations of c-Kit at Codon 816 Confer Drug Resistance in Human Leukemia Cells , 2001, Leukemia & lymphoma.

[24]  Lisa Garrett,et al.  The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia , 1999, Nature Genetics.